← ANALYSTS · TIPRANKS
Joon Lee · UBS
Hits
58%
278 of 483 ratings made money (TipRanks, all the analyst’s ratings)
Average return of a rating
+36.3%
Over a year after the rating, TipRanks’ measure
Our companies rated now
20
Buy / hold / sell: 16 / 4 / 0
Upside of the analyst’s targets
+73.0%
Average over 13 current targets, to the last price
The market’s answer to the ratings
+2.6%
Day-0 move against SPY in the rating’s direction, average over 12 upgrades, downgrades and target changes
| Date · added, NY | Stock | Action | Rating | Price target | Upside | Move vs SPY | |
|---|---|---|---|---|---|---|---|
| Oct 14on TipRanks Oct 15 06:55 | BMRNBioMarin Pharmaceutical · $10.8B | Assigned | Buy | $114 → $88.00−22.8% | +60.9% | +2.5%next day +1.4% | ↗ |
| Oct 14on TipRanks Oct 15 04:35 | QUREuniQure · $1.5B | Reiterated | Buy | $27.00 → $48.00+77.8% | +120.4% | −0.4%next day +7.1% | ↗ |
| Oct 14on TipRanks 19:50 | REGNQQQSPYRegeneron · $82.0B | Initiated | Buy | $660 → $978+48.2% | +23.7% | +2.0%next day +0.4% | ↗ |
| Oct 14on TipRanks 19:50 | ALNYQQQAlnylam Pharma · $31.3B | Reiterated | Buy | $550 → $354−35.6% | +52.7% | +4.0%next day +0.2% | ↗ |
| Oct 14on TipRanks 19:50 | BBIOBridgeBio Pharma · $12.4B | Reiterated | Buy | $82.00 → $92.00+12.2% | +38.6% | +3.1%next day 0.0% | ↗ |
| Oct 14on TipRanks 19:50 | IONSIonis Pharmaceuticals · $7.0B | Upgrade | Buy | $46.00 → $88.00+91.3% | +104.9% | +3.0%next day −1.6% | ↗ |
| Oct 14on TipRanks 19:50 | SLDBIWMSolid Biosciences · $615M | Initiated | Buy | $20.00 | +261.7% | +4.7%next day −2.6% | ↗ |
| Oct 14on TipRanks 19:50 | CRSPIWMCrispr Therapeutics AG · $5.0B | Initiated | Hold | $52.00 | +5.6% | +2.3%next day −3.3% | ↗ |
| Oct 14on TipRanks 19:50 | RAREIWMUltragenyx Pharmaceutical · $1.5B | Initiated | Hold | $16.00 | +10.0% | +1.5%next day −3.0% | ↗ |
| Oct 14on TipRanks 19:50 | PTCTIWMPTC Therapeutics · $5.1B | Assigned | Buy | $80.00 → $90.00+12.5% | +51.9% | +1.9%next day −1.8% | ↗ |
| Oct 14on TipRanks 19:50 | ASNDAscendis Pharma · $13.9B | Reiterated | Buy | $307 → $269−12.4% | +19.4% | −0.5%next day +0.5% | ↗ |
| Oct 14on TipRanks 19:50 | PRAXIWMPraxis Precision Medicines · $6.9B | Initiated | Buy | $706 | +192.0% | +3.6%next day −1.5% | ↗ |
| Mar 17on TipRanks 07:25 | EDITIWMEditas Medicine · $375M | Reiterated | Hold | — | — | −3.4%next day −3.1% · 5 days −6.2% | ↗ |
| Mar 17on TipRanks 07:25 | VYGRIWMVoyager Therapeutics · $124M | Reiterated | Buy | — | — | −9.5%next day −2.7% · 5 days +2.4% | ↗ |
| Mar 9on TipRanks 07:30 | ANABIWMAnaptysBio · $1.5B | Reiterated | Hold | $36.00 → $50.00+38.9% | +7.3% | +6.9%next day +4.0% · 5 days +9.9% | ↗ |
| Mar 3on TipRanks 08:15 | BMRNBioMarin Pharmaceutical · $10.8B | Reiterated | Buy | — | — | −1.1%next day +2.5% · 5 days +4.5% | ↗ |
| Mar 2on TipRanks 08:15 | CRSPIWMCrispr Therapeutics AG · $5.0B | Reiterated | Buy | — | — | +1.0%next day −3.6% · 5 days −2.1% | ↗ |
| Mar 2on TipRanks 08:15 | NTLAIWMIntellia Therapeutics · $1.6B | Reiterated | Buy | — | — | +12.0%next day −11.0% · 5 days −8.9% | ↗ |
| Feb 27on TipRanks 09:05 | PTCTIWMPTC Therapeutics · $5.1B | Reiterated | Buy | — | — | +0.6%next day −2.7% · 5 days −5.9% | ↗ |
| Feb 26on TipRanks Feb 27 02:35 | ALKSIWMAlkermes · $6.7B | Reiterated | Buy | — | — | −0.4%next day −1.6% · 5 days −6.6% | ↗ |
| Feb 13on TipRanks 08:15 | RAREIWMUltragenyx Pharmaceutical · $1.5B | Reiterated | Buy | $90.00 → $76.00−15.6% | +422.7% | −12.8%next day −1.8% · 5 days +9.6% | ↗ |
| Nov 10on TipRanks 10:00 | RAPPIWMRapport Therapeutics, Inc. · $1.4B | Reiterated | Buy | — | — | −4.4%next day +2.1% · 5 days +3.1% | ↗ |
| Nov 6on TipRanks 09:30 | LRMRIWMLarimar Therapeutics · $207M | Reiterated | Buy | — | — | +8.8%next day −0.4% · 5 days −5.4% | ↗ |
| Nov 5on TipRanks 09:20 | TSHAIWMTaysha Gene Therapies · $1.2B | Reiterated | Buy | — | — | −6.0%next day −1.7% · 5 days +7.3% | ↗ |
| No ratings for this filter. | |||||||
Ratings of the stocks the collector reads (the companies of QQQ, SPY, IWM, SMH, SOXL and SOXS and the other US stocks of TipRanks’ feed of new ratings) that it has kept: every new one since 30 September 2026, before that the analyst’s latest rating of each company. Upside is the target over the stock’s last price. The analyst at TipRanks ↗